Patents by Inventor Peter Oettgen

Peter Oettgen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110071142
    Abstract: The present invention relates to methods of identifying small molecule candidate agents capable of modulating transcription factor function such that the function/expression of a target transcription factor and/or proteins downstream of this target protein comprises the screening of small molecule libraries using in silico high throughput docking for candidate small molecules/agents that are selectively identified for their ability to target and disrupt the transcription factor-DNA interface through unique transcription factor and/or DNA descriptors that are defined within a pharmacophore, and then testing/evaluating the candidate agents identified above through one or more in vitro assays for their ability to modulate transcription factor function including expression of this target protein and/or proteins that are downstream of the target transcription factor. The present invention also relates to various compounds described herein (e.g.
    Type: Application
    Filed: March 19, 2010
    Publication date: March 24, 2011
    Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER
    Inventors: Peter Oettgen, Alan C. Rigby, Towia Libermann
  • Publication number: 20100120754
    Abstract: The present invention relates to methods of identifying small molecule candidate agents capable of modulating transcription factor function such that the function/expression of a target transcription factor and/or proteins downstream of this target protein comprises the screening of small molecule libraries using in silico high throughput docking for candidate small molecules/agents that are selectively identified for their ability to target and disrupt the transcription factor-DNA interface through unique transcription factor and/or DNA descriptors that are defined within a pharmacophore, and then testing/evaluating the candidate agents identified above through one or more in vitro assays for their ability to modulate transcription factor function including expression of this target protein and/or proteins that are downstream of the target transcription factor.
    Type: Application
    Filed: May 6, 2009
    Publication date: May 13, 2010
    Inventors: Peter Oettgen, Alan Rigby, Towia Libermann
  • Patent number: 6960444
    Abstract: This invention relates to methods of modulating the development of blood vessels and/or endothelial cell differentiation in a mammal comprising altering the activity of an Ets transcription factor, which activates vascular specific genes. More particularly, the transcription factor comprises ELF-1, and transcription factors that are homologous to ELF-1. The invention further relates to methods of screening for compounds that affect the activity of these transcription factors, and therefore, affect the development of blood vessels and/or endothelial cell differentiation. The invention also relates to methods of using these compounds to treat diseases, or symptoms of diseases, by either increasing or decreasing blood vessel development and/or endothelial cell differentiation.
    Type: Grant
    Filed: May 28, 2003
    Date of Patent: November 1, 2005
    Assignee: Beth Israel Deaconess Medical Center
    Inventors: Peter Oettgen, Towia Libermann
  • Patent number: 6869929
    Abstract: The present invention provides a method of treating inflammation in a mammal comprising altering the activity of a transcription factor involved in the inflammatory response. The invention also relates to the use of transcription factors to screen compounds that are capable of reducing inflammation. The invention also relates to the use of transcription factors in methods of diagnosing the presence of an inflammatory disease in a tissue of a mammal and methods of monitoring the treatment of an inflammatory disease in a tissue of a mammal.
    Type: Grant
    Filed: March 20, 2003
    Date of Patent: March 22, 2005
    Assignee: Beth Israel Deaconess Medical Center
    Inventors: Peter Oettgen, Towia Libermann, Mary Goldring
  • Publication number: 20040197345
    Abstract: The present invention relates to a novel human protein called Prostate Derived Ets Factor, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.
    Type: Application
    Filed: May 5, 2004
    Publication date: October 7, 2004
    Applicants: Human Genome Sciences, Inc., Beth Israel Deaconess Medical Center
    Inventors: Towia Aron Libermann, Joerg Peter Oettgen, Charles A. Kunsch, Gregory A. Endress, Craig A. Rosen
  • Publication number: 20040091468
    Abstract: This invention relates to methods of modulating the development of blood vessels and/or endothelial cell differentiation in a mammal comprising altering the activity of an Ets transcription factor, which activates vascular specific genes. More particularly, the transcription factor comprises ELF-1, and transcription factors that are homologous to ELF-1. The invention further relates to methods of screening for compounds that affect the activity of these transcription factors, and therefore, affect the development of blood vessels and/or endothelial cell differentiation. The invention also relates to methods of using these compounds to treat diseases, or symptoms of diseases, by either increasing or decreasing blood vessel development and/or endothelial cell differentiation.
    Type: Application
    Filed: May 28, 2003
    Publication date: May 13, 2004
    Inventors: Peter Oettgen, Towia Libermann
  • Publication number: 20030229003
    Abstract: The present invention provides a method of treating inflammation in a mammal comprising altering the activity of a transcription factor involved in the inflammatory response. The invention also relates to the use of transcription factors to screen compounds that are capable of reducing inflammation. The invention also relates to the use of transcription factors in methods of diagnosing the presence of an inflammatory disease in a tissue of a mammal and methods of monitoring the treatment of an inflammatory disease in a tissue of a mammal.
    Type: Application
    Filed: March 20, 2003
    Publication date: December 11, 2003
    Inventors: Peter Oettgen, Towia Libermann, Mary Goldring
  • Publication number: 20010010934
    Abstract: The present invention relates to a novel human protein called Prostate Derived Ets Factor, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.
    Type: Application
    Filed: July 31, 1998
    Publication date: August 2, 2001
    Inventors: TOWIA ARON LIBERMANN, JOERG PETER OETTGEN, CHARLES A. KUNSCH, GREGORY A. ENDRESS, CRAIG A. ROSEN
  • Patent number: 5721113
    Abstract: Isolated nucleic acids encoding human lymphoid-specific transcription factors NERF-1 and NERF-2, proteins obtainable from the nucleic acids, recombinant host cells transformed with the nucleic acids and use of the proteins and nucleic acid sequences are dislcosed.
    Type: Grant
    Filed: January 3, 1995
    Date of Patent: February 24, 1998
    Assignee: Human Genome Sciences, Inc.
    Inventors: Towia Aron Libermann, Joerg Peter Oettgen, Charles A. Kunsch